Generic Name and Formulations:
Dorzolamide HCl 2%, timolol maleate 0.5%; oph soln; contains benzalkonium chloride.
Indications for COSOPT:
Open-angle glaucoma or ocular hypertension where β-blocker alone is inadequate.
Adults and Children:
<2yrs: not recommended. 1 drop twice daily.
Asthma or history of asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock.
Mild-to-moderate COPD or bronchospastic disease, or severe renal impairment: not recommended. Hepatic impairment. Surgery. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Discontinue if ocular effects occur. Soft contact lenses (remove, may reinsert 15 minutes after instillation). Discontinue at 1st sign of cardiac failure. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant oral carbonic anhydrase inhibitors or other topical β-blockers: not recommended. May potentiate systemic β-blockers, reserpine, hypoglycemic agents, and mydriatic effects of topical epinephrine. May be potentiated by quinidine. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis). Possible conduction defects, left ventricular failure, or hypotension with calcium channel blockers, digoxin. May block epinephrine.
Carbonic anhydrase inhibitor (sulfonamide) + noncardioselective beta-blocker.
Taste perversion; ocular burning, stinging, or itching; conjunctival hyperemia, blurred vision, superficial punctate keratitis; possible systemic effects.
Cosopt—10mL; Cosopt PF—60 (single-use 0.2mL containers)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|